Company: AZN
Filing Date: 2025-09-29
Form Type: 6-K
Source: 0001104659-25-094039
Chunk: 10

Company: ASTRAZENECA PLC
Filing Date: 2025-09-29
Form: 6-K
Chunk 10
---
 AstraZeneca ADSs will be cancelled in exchange for the right to receive or direct delivery of the number of AstraZeneca Shares they represent.

•

Settlement System Migration: in order to implement the Harmonised Listing Structure, the New Articles will be used to effect the Settlement System Migration, without any change in practice to Shareholders’ ownership rights in respect of such AstraZeneca Shares or the economic rights attaching to them (save in respect of fractional entitlements in respect of AstraZeneca ADSs). In practice, Shareholders trading uncertificated AstraZeneca Shares on the NYSE, London Stock Exchange (settling in the form of AstraZeneca DIs) or Nasdaq Stockholm following the implementation of the Harmonised Listing Structure will continue to have substantially the same trading and settlement experience as they have today (including in respect of such AstraZeneca Shares which are currently traded in the form of AstraZeneca ADSs). See Part III ( Settlement and Dealings in AstraZeneca Shares following the Settlement System Migration**

#### ) of this document for further details.
•

Change of registrar: prior to, and in preparation for, the implementation of the Harmonised Listing Structure, AstraZeneca proposes to transfer the management of the Register from Equiniti Limited to Computershare Investor Services PLC. Shareholders will be notified once the change has become effective. From the Effective Time, the Register will be administered in the United States by CTCNA.

As stated in the letter from the Chair set out in Part I ( Letter from the Chair of AstraZeneca PLC ) of this document, Shareholder approval is now being sought for the Harmonised Listing Structure by way of approval of certain amendments to AstraZeneca’s Existing Articles which are required to implement the Settlement System Migration. A consequence of the Settlement System Migration is that the trading and settlement of AstraZeneca Shares on the London Stock Exchange will no longer occur directly through the CREST settlement system. Instead, interests in AstraZeneca Shares will be held, settled and transferred through CREST in the form of AstraZeneca DIs, with each AstraZeneca DI representing an entitlement to one underlying AstraZeneca Share. Further details of these arrangements are set out in Part III ( Settlement and Dealings in AstraZeneca Shares following the Settlement System Migration ) of this document. The adoption of the New Articles is the most practical way to enable AstraZeneca to implement these arrangements.

The implementation of the